EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Natural Products as a Pipeline for Next-Generation Neurodegenerative Drugs: From Single-Target Failure to Multi-Target Opportunity in Alzheimer’s and Parkinson’s Disease

Solomon Habtemariam iD

Molecules · 29.04.2026 · 31 (9) · 1489

DOI: 10.3390/molecules31091489 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 29.04.2026. Verfasst von Solomon Habtemariam. Beteiligte Einrichtung: Pharmacognosy Research & Herbal Analysis Services UK, 124 City Road, London EC1V 2NX, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Biological Products, Alzheimer Disease, Drug Discovery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) represent some of the most complex and therapeutically challenging disorders in modern medicine. Despite decades of research, the traditional one drug–one target paradigm has largely failed to deliver disease-modifying therapies. Increasing evidence suggests that these complex diseases arise from interconnected pathological networks involving protein aggregation, oxidative stress, mitochondrial dysfunction, neuroinflammation, and synaptic loss. In this context, natural products (NPs) have re-emerged as a promising pipeline for next-generation therapeutics. Unlike conventional small molecules, NPs inherently exhibit polypharmacology, targeting multiple pathways simultaneously. Recent advances (2019–2026) demonstrate a paradigm shift, from crude NPs and single-mechanism compounds toward engineered derivatives, network pharmacology, and multi-target drug design. Using AD and PD as case studies, this review critically evaluates how NPs are redefining drug discovery by highlighting key emerging NPs, translational strategies, and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseBiological ProductsAlzheimer DiseaseDrug DiscoveryNeuroprotective AgentsHumansAnimalsDrug Design

Stichwörter der Autor:innen

Alzheimer’s diseaseParkinson’s diseasedrug discoverymulti-target drug designnetwork pharmacologyneurodegenerative diseasesone drug–one targetpolypharmacologytranslational strategies

Substanzen

Biological ProductsNeuroprotective Agents

Autor:innen und Institutionen

  • Pharmacognosy Research & Herbal Analysis Services UK, 124 City Road, London EC1V 2NX, UK.

ORCID-Profile: Solomon Habtemariam

Zitieren

APA

Habtemariam, S. (2026). Natural Products as a Pipeline for Next-Generation Neurodegenerative Drugs: From Single-Target Failure to Multi-Target Opportunity in Alzheimer’s and Parkinson’s Disease. Molecules, 31(9), 1489. https://doi.org/10.3390/molecules31091489

Vancouver

Habtemariam S. Natural Products as a Pipeline for Next-Generation Neurodegenerative Drugs: From Single-Target Failure to Multi-Target Opportunity in Alzheimer’s and Parkinson’s Disease. Molecules. 2026;31(9):1489. doi:10.3390/molecules31091489

BibTeX
@article{Habtemariam2026,
  author = {Habtemariam, Solomon},
  title = {Natural Products as a Pipeline for Next-Generation Neurodegenerative Drugs: From Single-Target Failure to Multi-Target Opportunity in Alzheimer’s and Parkinson’s Disease},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {9},
  pages = {1489},
  doi = {10.3390/molecules31091489}
}
Kostenlos starten →